XERS Stock Analysis: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$7.40
0.20 (2.78%)
▲
5d:
+7.25%
30d:
+19.55%
90d:
+39.89%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 4.0/10
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: XERS is 7.4% above its trading range ($6.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: XERS is 7.4% above its trading range ($6.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.38
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.93
17.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $7.40, which is considered extended relative to its 30-day fair value range of $6.05 to $6.89. The stock's valuation (Forward PE: 18.7) is in line with its historical norms (18.7). At these levels, the market is pricing in 0.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XERS is showing sideways momentum. The price is approaching resistance at $7.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XERS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+52.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XERS is showing sideways momentum. The price is approaching resistance at $7.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XERS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+52.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.05 -
$6.89
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BEARISH: Price extended above range (+7.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 52.5% below Wall St target ($11.29)
- NEUTRAL: Market pricing in 0.0% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$6.05 -
$6.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.51
Resistance Level
$7.51
Current Trend
Sideways
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.73
Wall Street Target
$11.29
(+52.5%)
Revenue Growth (YoY)
38.3%
Profit Margin
3.8%
PE vs Historical
18.7 vs 18.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
0%
(market-implied from PE analysis)
1-Year Target
$7.40
(0%)
2-Year Target
$7.40
(0%)
3-Year Target
$7.40
(0%)
3-Yr Target (if PE normalizes)
(PE: 19→19)
PE COMPRESSION
$7.39
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 177.2%)
$29.04
(+292%)
Base:
(SPY PE: 18.7, Growth: 177.2%)
$24.98
(+238%)
Bear:
(PE: 15.9, Growth: 177.2%)
$21.23
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (86x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Forward PE: 86.21 | Forward EPS (Implied): $0.09
Bull Case
$8.94
(+21%)
Analyst growth 15.0%, PE expands to 90.5
Base Case
$7.40
(0%)
Market implied 0.0%, PE stable at 86.2
Bear Case
$5.66
(-24%)
Severe decline -15.0%, PE contracts to 77.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 25, 2026 12:47 AM ET
Data refreshes hourly during market hours. Next update: 1:47 AM
Data refreshes hourly during market hours. Next update: 1:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-04-01
James Aloysius Brady
SELL
10834 shares
2026-03-30
Beth Hecht
SELL
16667 shares
2026-03-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |